HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 09:16:50 03/06/2024 pm IST | ||
| 6.42 EUR | +2.56% |
|
| 1 month | +2.96% | ||
| 3 months | +61.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 6.42 | +2.56% |
| 31/24/31 | 6.26 | +3.13% |
| 30/24/30 | 6.07 | +2.19% |
| 29/24/29 | 5.94 | -1.66% |
| 28/24/28 | 6.04 | -5.18% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 09:16 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TY2 |
| ISIN | DE000HR5TY24 |
| Date issued | 25/02/2021 |
| Strike | 6,878 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.13 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.69 € |
|---|---|
| Lowest since issue | 0.76 € |
| Spread | 0.03 € |
| Spread % | 0.47% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
